In The News
ConstructionPRO Test 1
ConstructionPRO Test 2
ConstructionPRO Test 3
ConstructionPRO Test 4
ConstructionPRO Test 5
ConstructionPRO Test 6
ConstructionPRO Test 7
High Court rejects Qantas appeal in ground crew sacking case
I’m afraid AI can’t do that: Law firms say smart tech uses limited
Lawyer’s defamation case fails serious harm test, judge finds
Mesoblast hit with shareholder class action over stem cell treatment
Class Actions 2022-05-19 4:16 pmBy Sam Matthews | Melbourne
Please login to bookmark Close

Regenerative medicine company Mesoblast is facing another class action over claims it misled shareholders about the potential application of a developmental stem cell product to treat terminally ill children.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au